NCT03229200 2025-10-30Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Pharmacyclics Switzerland GmbHPhase 4 Active not recruiting297 enrolled
NCT03162536 2025-09-08ARQ 531-101ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1/2 Active not recruiting190 enrolled